ライフサイエンスコーパス: PVR

1 PVR after repair of tetralogy of Fallot has a low and im

2 PVR and mean pulmonary arterial pressure were not signif

3 PVR areas seen on a short-axis view were measured immedi

4 PVR before RVESVi reaches 82 mL/m(2) confers optimal cha

5 PVR is more frequent with TAVR than surgical aortic valv

6 PVR is potentially a reliable indicator of bone graft in

7 PVR might be treated by rational repositioning of existi

8 PVR monitoring during the follow-up of patients with pul

9 PVR rate diminished from 14.1% in S1 to 8.1% in S2 (P =

10 PVR uncommonly develops after successful treatment of re

11 PVR was clinically graded on days 3, 7, and 14.

12 PVR was compared with the van Hemert scale scores and an

13 reoretinopathy (PVR; n = 917), (2) grade C-1 PVR (n = 637), (3) choroidal detachment or significant h

14 The difference between grade B and C-1 PVR was significant (P = 2 x 10(-6)).

15 detachment, significant hypotony, grade C-1 PVR, 4 detached quadrants, and large or giant retinal br

16 Multivariate analysis showed grade C-1 PVR, 4 detached quadrants, and presence of choroidal det

17 With grade B or C-1 PVR, cases with large or giant tears had significantly h

18 In grade C-1 PVR, there was no statistically significant difference i

19 silicone oil in patients with grade B or C-1 PVR.

20 ed a reduction in PVR severity of at least 1 PVR class at 1 year.

21 the early control of CMV through the DNAM-1-PVR pathway.

22 In total, 221 PVRs were performed in 220 patients (130 male patients;

23 istance (PVR) 593 +/- 127 versus 495 +/- 70 (PVR-dyn.s/cm), and oxygenation 327 +/- 32 versus 330 +/-

24 Compared with segments without PVR (n=758), PVR segments (n=44) were characterized by lower Delta-Im

25 ts of control patients and those with PVR-A, PVR-B, and PVR-C (n = 10 for each group).

26 We studied whether acute PVR (adenosine and waiting time) and late PVR (at repeat

27 Additionally, PVR was estimated from CMR data (PA velocity and right v

28 al retinotomy for the management of advanced PVR (grade D) were included in the analysis.

29 T cells and mTOR signaling, whereas advanced PVR is characterized by a chronic monocyte response.

30 rformed before PVR (pPVR), immediately after PVR (median, 6 d), and midterm after PVR (mPVR; median,

31 astolic volume pPVR versus immediately after PVR versus mPVR, 156.1+/-41.9 versus 104.9+/-28.4 versus

32 L/m(2); RVESVi pPVR versus immediately after PVR versus mPVR, 74.9+/-26.2 versus 57.4+/-22.7 versus 5

33 rse remodeling takes place immediately after PVR, followed by a continuing process of further biologi

34 ng intrinsic RV functional improvement after PVR.

35 y after PVR (median, 6 d), and midterm after PVR (mPVR; median, 3 y).

36 n mean renal cortical tissue perfusion after PVR when compared with Voluven (P = 0.033).

37 Survival after PVR in the later era (2005-2010; n=156) was significantl

38 of this meta-analysis demonstrate that after PVR: 1) the RV experiences improvement of its volumes an

39 Events in the first year after PVR are rare, and in select high-risk patients, surgical

40 In the first year after PVR, 2 events occurred.

41 ation, a single event occurred 7 years after PVR.

42 nt with blocking antibodies directed against PVR, DNAM-1, PECAM, and CD99 showed that endothelial PVR

43 after hour 2 (265 +/- 44 vs 207 +/- 44), and PVR started to increase after hour 3 (765 +/- 132 vs 916

44 ral target proteins, including the NTB-A and PVR receptors and the host restriction factor tetherin,

45 ol patients and those with PVR-A, PVR-B, and PVR-C (n = 10 for each group).

46 car in the evaluation of TAVR candidates and PVR assessment in the postimplant patient are promising,

47 artery wedge pressure [PAWP]</=15 mm Hg and PVR>3 WU).

48 o cause paralytic disease in both humans and PVR-Tg21 transgenic mice, loss of the temperature-sensit

49 d, second classification based upon lens and PVR status and third classification based upon AL of the

50 er disease and POPH (as assessed by MELD and PVR, respectively) were significantly associated with wa

51 Overall, these data reveal that MICA and PVR are directly regulated by HCMV IE proteins, and this

52 Drug-induced MICA and PVR gene expression are transcriptionally regulated and

53 nd IE2 stimulated the expression of MICA and PVR, but not ULBP3.

54 Age averaged 61.3+/-14.8 years, muPAWP and PVR were 16.4+/-7.1 mm Hg and 6.3+/-4.0 WU, respectively

55 ent in anatomical and functional outcome and PVR rate occurred in participating centres cannot be att

56 re, pulmonary vascular resistance [PVR], and PVR and PA pressure-flow response [DeltaPQ] during exerc

57 s (complete/posterior reattachment rates and PVR recurrence) were comparable between the 2 groups.

58 Foveal RPE atrophy, CNV recurrence, and PVR carried a worse prognosis.

59 ge HCMV strains upregulated MICA, ULBP3, and PVR, with NKG2D and DNAM-1 playing a role in NK cell-med

60 106 mmol/L, respectively, after Voluven and PVR infusion (P = 0.032).

61 CAM, activation of endothelial PVR with anti-PVR antibodies or interaction with its ligand, DNAM-1, r

62 and cytokines that accumulate in vitreous as PVR develops, neutralizing vascular endothelial growth f

63 At PVR-TIPS completion, persistence of MPV thrombus was not

64 In grade B PVR, the level 1 failure rate was higher when treated wi

65 vascular magnetic resonance performed before PVR (pPVR), immediately after PVR (median, 6 d), and mid

66 showed a strong negative association between PVR values and van Hemert scale scores, as the healing p

67 Dasatinib also prevented TRD caused by PVR in vivo.

68 traction retinal detachment (TRD) caused by PVR.

69 rent inferior retinal detachment and grade C PVR after primary encircle scleral buckling (SB group -

70 ent inferior retinal detachment with grade C PVR in phakic eyes.

71 highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hind

72 However, the extent to which the TIGIT/CD226/PVR-axis is affected by HIV-infection has not been chara

73 ioactivity of both experimental and clinical PVR vitreous.

74 its in 12 eyes after surgery for complicated PVR detachments using retinectomies with oil, with an av

75 In conclusion, PVR seems to be a positive approach in the analyzed scen

76 Early PVR is characterized by activation of T cells and mTOR s

77 Early PVR vitreous showed upregulation of T-cell markers, prof

78 with elevated PVR, and the cause of elevated PVR may be other factors such as pain or anxiety causing

79 on in the majority of patients with elevated PVR, and the cause of elevated PVR may be other factors

80 h leukocyte PECAM, activation of endothelial PVR with anti-PVR antibodies or interaction with its lig

81 M-1, PECAM, and CD99 showed that endothelial PVR and monocyte DNAM-1 interact at and regulate a step

82 In case of established PVR >/= C1, the reattachment rate was not statistically

83 oil for retinal detachment with established PVR (Grade C) were randomized to standard (control) or s

84 CMR-estimated PVR showed adequate agreement with invasive PVR (mean bi

85 eks there were improvements in mean exercise PVR (85.8 dynes x second/cm(5) ; P = 0.003) and mean dis

86 e particularly well correlated with exercise PVR and DeltaPQ.

87 n vitro and prevented TRD in an experimental PVR model in the swine without any detectable toxicity.

88 alpha (PDGFRalpha) and driving experimental PVR.

89 or alpha, which is required for experimental PVR and is associated with this disease in humans.

90 SV inhibited the progression of experimental PVR in rabbit eyes.

91 Our swine model of experimental PVR with green fluorescent protein-positive (GFP+) RPE c

92 a literature focusing on the indications for PVR.

93 ing vitrectomy surgery with silicone oil for PVR.

94 es to neutralize VEGF-A are prophylactic for PVR, and that anti-VEGF-based therapies may be effective

95 Both IE proteins were instead required for PVR upregulation via a mechanism independent of IE DNA b

96 etinectomies with silicone oil tamponade for PVR-related retinal detachments.

97 Once formed, PVR is difficult to treat.

98 ential expression of specific cytokines from PVR-A to C.

99 n-approved agents could protect the eye from PVR in multiple animal models and to further investigate

100 of 50 survivors (age, 4-57 years) free from PVR underwent cardiovascular magnetic resonance, echocar

101 Survival and freedom from PVR were tracked in 1085 consecutive patients receiving

102 afely and effectively protected rabbits from PVR in multiple models of disease.

103 CD74) and adhesion molecule pathways (e.g., PVR and ICAM1).

104 years, both lower PAC (P<0.0001) and higher PVR (P<0.0001) portend more adverse clinical events (all

105 clinical setting because it prevented human PVR vitreous-induced contraction of cells isolated from

106 n MERIT-1, macitentan significantly improved PVR in patients with inoperable CTEPH and was well toler

107 In PVR vitreous, 29 cytokines were upregulated compared to

108 VR in chronic PH (n = 22); and 3) changes in PVR during vasodilator testing in chronic PH (n = 10).

109 embolization (n = 10); 2) serial changes in PVR in chronic PH (n = 22); and 3) changes in PVR during

110 e monitoring of acute and chronic changes in PVR in PH.

111 l analysis were used to correlate changes in PVR with changes in CMR-quantified PA velocity.

112 y of CMR to monitor: 1) an acute increase in PVR generated by acute pulmonary embolization (n = 10);

113 inversely correlated with acute increases in PVR induced by pulmonary embolization (r = -0.92), seria

114 GFs, which, at the concentrations present in PVR vitreous, inhibited non-PDGF-mediated activation of

115 There was significant reduction in PVR area attributable to PD (21.7+/-9.3 mm(2); P<0.0001)

116 oderate PVR at 30 days showed a reduction in PVR severity of at least 1 PVR class at 1 year.

117 ided into two series based upon variation in PVR rate determined by logistic regression analysis.

118 Factors that increase PVR, including an increase in residential altitude, may

119 choroidal detachment or hypotony, increasing PVR was associated with increasing level 1 failure rates

120 PVR-mediated cell adhesion and TIGIT-induced PVR phosphorylation in primary dendritic cells.

121 n vitro, and HC-HA/PTX3's ability to inhibit PVR formation warrants evaluation in an animal model.

122 Dasatinib significantly inhibited PVR-related RPE changes in vitro and prevented TRD in an

123 ; 95% CI, 1.05-1.17; P < 0.001), and initial PVR (HR, 1.12 per 100 dynes.s.cm; 95% CI, 1.02-1.23; P =

124 PVR showed adequate agreement with invasive PVR (mean bias -1.1 Wood units,; 95% confidence interval

125 In CF-guided pulmonary vein isolation, PVR is explained by lack of both lesion depth and contig

126 y by binding to the receptor tyrosine kinase PVR, which is necessary and sufficient for intestinal ER

127 PD patients had larger PVR areas immediately after deployment (40.3+/-17.1 vers

128 te PVR (adenosine and waiting time) and late PVR (at repeat) are explained by incomplete transmuralit

129 characteristics of survivors free from late PVR and with good exercise capacity are not well describ

130 ion (IL-2, IL-6, and IL-13), whereas in late PVR vitreous, cytokines driving monocyte responses and s

131 -stimulatory receptor CD226 and their ligand PVR are altered in viral infections and cancer.

132 At week 16, geometric mean PVR decreased to 73.0% of baseline in the macitentan gro

133 ree independent observers (A, B, C) measured PVRs at two different time points during the first and t

134 ucing PVR in patients with greater than mild PVR after balloon-expandable TAVR.

135 mized an ARPE-19 cell culture model to mimic PVR by defining cell density, growth factors, and cultiv

136 ould be positioned successfully with minimal PVR.

137 roke was 1.7%; 1 (1.0%) patient had moderate PVR, whereas none had severe PVR.

138 Most patients with at least moderate PVR at 30 days showed a decrease of PVR severity grade a

139 , 73% of the patients with at least moderate PVR at 30 days showed a reduction in PVR severity of at

140 to moderate, and 3.5% had at least moderate PVR at 30 days.

141 Only patients with at least moderate PVR had higher 1-year mortality (hazard ratio [HR], 2.40

142 R with the SAPIEN 3 valve, at least moderate PVR was rare but associated with increased risk of death

143 stically different (92.6%) from eyes with no PVR (91.1%) irrespective of lens status.

144 t codon 72 between the PVR cases and the non-PVR controls in Spain and Portugal (phase I), but not in

145 Prespecified analysis of PVR in the Placement of Aortic Transcatheter Valves (PAR

146 of p53 was a required event in two assays of PVR (namely, platelet-derived growth factor receptor alp

147 eived a SAPIEN 3 valve and had assessment of PVR.

148 etinal detachment fails primarily because of PVR.

149 ical and histopathologic characterization of PVR in treated retinoblastoma.

150 is the most vision-compromising component of PVR.

151 moderate PVR at 30 days showed a decrease of PVR severity grade at 1 year.

152 est subjects (n = 7) with varying degrees of PVR.

153 rapeutic agent to prevent the development of PVR by targeting EMT of RPE.

154 specificity, can inhibit the development of PVR in fibroblast and Muller cell rabbit models of PVR.

155 found to be intrinsic to the development of PVR in rabbit models.

156 e of this polymorphism in the development of PVR.

157 udies that reported data about the effect of PVR in patients with repaired tetralogy of Fallot that d

158 We assessed the effect of PVR on 1-year mortality and heart failure rehospitalizat

159 perative RV geometry modulates the effect of PVR; and 6) there is important heterogeneity of the effe

160 PAC bundles the effects of PVR and left-sided filling pressures on RV afterload, ex

161 Furthermore, expression of PVR was increased on CD4(+) T cells, especially T follic

162 We evaluated the impact of PVR-TIPS on liver function, transplant eligibility, and

163 SU9518 was an effective inhibitor of PVR in both fibroblast and Muller cell models of PVR.

164 SU9518 is an effective and safe inhibitor of PVR in rabbit models, and could potentially be used in h

165 Likely mediators of PVR are growth factors in vitreous, which stimulate cell

166 and retinal detachment in an animal model of PVR).

167 V on PVR development using a rabbit model of PVR.

168 in both fibroblast and Muller cell models of PVR.

169 fibroblast and Muller cell rabbit models of PVR.

170 evolution, and effect on 1-year outcomes of PVR following TAVR with a third-generation balloon-expan

171 The outcomes of PVR in adults after repair of tetralogy of Fallot at a s

172 he cluster was achieved by overexpression of PVR in the absence of ligand or by overexpression of fus

173 ls is a critical step in the pathogenesis of PVR, which is characterized by fibrotic membrane formati

174 can be used to study the pathophysiology of PVR, as well as new novel therapies.

175 g PVR at week 16, expressed as percentage of PVR measured at baseline.

176 atinib may be effective in the prevention of PVR.

177 Centres with higher rates of PVR in S1 showed the greatest reductions in S2.

178 higher level 2 failure rates, regardless of PVR status (P<0.05).

179 Spontaneous regression of PVR was seen in both groups.

180 morphism is associated with a higher risk of PVR developing after a primary RD.

181 d begin to define the mechanism and risks of PVR after TAVR.

182 specific therapeutic target and the stage of PVR.

183 tially life-threatening issue at the time of PVR.

184 er examined the preventive effect of RESV on PVR development using a rabbit model of PVR.

185 s-homodimer, each TIGIT molecule binding one PVR molecule.

186 icant elevation of pulmonary hypertension or PVR or uncontrolled RVF after aggressive management with

187 ived 1-L intravenous infusions of Voluven or PVR over 30 minutes in a randomized, double-blind manner

188 and macular volume; (3) development of overt PVR recurrence; (4) complete and posterior retinal reatt

189 contraction of cells isolated from a patient PVR membrane.

190 ssociated with a smaller improvement in post-PVR RV/left ventricular ejection fraction.

191 e aimed to assess immediate and midterm post-PVR changes and predictors of reverse remoeling.

192 as an independent predictor of postoperative PVR development (P = .035) and resulted in an area under

193 Preoperative PVR was the only clinical variable that was an independe

194 (VEGF) A has recently been found to prevent PVR in at least one animal model.

195 interest in developing approaches to prevent PVR.

196 Thus, VEGF promotes PVR by a noncanonical ability to engage platelet-derived

197 We examined if the pixel value ratio (PVR) obtained in routine follow-up digital radiographs c

198 49 of 2,231 patients); the pooled 5-year re-PVR was 4.9% (15 studies; 88 of 1,798 patients).

199 obliterated, we developed PV recanalization (PVR)-transjugular intrahepatic portosystemic shunt (TIPS

200 The poliovirus receptor (PVR) is a ubiquitously expressed glycoprotein involved i

201 d), Nectin-2/CD112, and poliovirus receptor (PVR)/CD155 (DNAM-1 ligand), are often induced on virus-i

202 he crystal structure of poliovirus receptor (PVR)/Nectin-like-5/CD155) in complex with its cognate im

203 with antibodies against poliovirus receptor (PVR; CD155) and DNAX-associated molecule-1 (DNAM-1; CD22

204 kinases (RTKs), PDGF/VEGF-related receptor (PVR) and EGFR, to read guidance cues secreted by the ooc

205 Pulmonary vein reconnection (PVR) still determines recurrences of atrial fibrillation

206 PS), a pressure visualization and recording (PVR) system with a spatial resolution of 500 microm is d

207 rch (potato-derived) [Plasma Volume Redibag (PVR); Baxter Healthcare, Thetford, United Kingdom] on re

208 are no pharmacological approaches to reduce PVR risk.

209 demonstrates the efficacy of PD at reducing PVR in patients with greater than mild PVR after balloon

210 Human cytomegalovirus (HCMV) down-regulates PVR expression, but the significance of this viral funct

211 re and even mild paravalvular regurgitation (PVR) are associated with increased mortality following t

212 Paravalvular regurgitation (PVR) is common after transcatheter aortic valve replacem

213 postimplantation paravalvular regurgitation (PVR), and the potential role of delayed enhancement asse

214 seal to minimize paravalvular regurgitation (PVR).

215 ve function and para-valvular regurgitation (PVR) after trans-catheter aortic valve replacement (TAVR

216 ns for surgical pulmonary valve replacement (PVR) after repair of tetralogy of Fallot have recently b

217 Pulmonary valve replacement (PVR) after repair of tetralogy of Fallot is commonly req

218 Pulmonary valve replacement (PVR) in patients with repaired tetralogy of Fallot provi

219 real benefit of pulmonary valve replacement (PVR) in patients with repaired tetralogy of Fallot who d

220 Fallot require pulmonary valve replacement (PVR), but the evaluation for and management of ventricul

221 An important proportion of patients require PVR late after tetralogy of Fallot repair.

222 stat-cm H2O), pulmonary vascular resistance (PVR) 593 +/- 127 versus 495 +/- 70 (PVR-dyn.s/cm), and o

223 rily elevated pulmonary vascular resistance (PVR) from those with PH predominantly because of elevate

224 n relation to pulmonary vascular resistance (PVR) in heart failure.

225 rm changes in pulmonary vascular resistance (PVR) noninvasively.

226 II-IV with a pulmonary vascular resistance (PVR) of at least 400 dyn.s/cm(5) and a walk distance of

227 pressures and pulmonary vascular resistance (PVR), effects reverse right ventricle and left ventricle

228 e part on low pulmonary vascular resistance (PVR).

229 >25 mm Hg and pulmonary vascular resistance [PVR] >/=240 dynes.s.cm) who were approved for a POPH MEL

230 PA pressure, pulmonary vascular resistance [PVR], and PVR and PA pressure-flow response [DeltaPQ] du

231 The primary endpoint was resting PVR at week 16, expressed as percentage of PVR measured

232 The m20.1 protein of MCMV retains PVR in the endoplasmic reticulum and promotes its degrad

233 date, 189 patients have undergone secondary PVR at mean age of 20+/-13 years (36% of those alive at

234 y pulmonary embolization (r = -0.92), serial PVR fluctuations in chronic PH (r = -0.89), and acute re

235 Three patients developed severe PVR after sequential thermal laser combined with systemi

236 treated retinoblastoma who developed severe PVR and required enucleation.

237 nt had moderate PVR, whereas none had severe PVR.

238 Finally, although VEGF could promote some PVR-associated cellular responses via VEGF receptors exp

239 e CMV (MCMV) also down-regulates the surface PVR.

240 We established a swine PVR model that recapitulates key clinical features found

241 nt (50% intramuscular paralytic dose in Tg21-PVR mice: log10(7.0)).

242 pressing the human poliovirus receptor (Tg21-PVR) mice, and their antigenicity was characterized by i

243 er prediction of significant RV failure than PVR (area under the curve ROC 0.74 versus 0.67, respecti

244 Further studies demonstrate that PVR resides in the recently identified lateral border re

245 The PVR from radiographs of thirty children with ceramic bon

246 The PVR-TIPS may be considered for patients with obliterativ

247 genotype frequencies at codon 72 between the PVR cases and the non-PVR controls in Spain and Portugal

248 and provide structural insights into how the PVR family of immunoregulators function.

249 A MCMV mutant lacking the PVR inhibitor was attenuated in normal mice but not in m

250 The reliability of the PVR measurements was assessed using an aluminum step wed

251 thesized that HC-HA/PTX3 could inhibit these PVR-related processes in vitro.

252 In this PVR system, the applied pressure can be recorded without

253 t the TIGIT/TIGIT interface limit both TIGIT/PVR-mediated cell adhesion and TIGIT-induced PVR phospho

254 for cell adhesion and signaling by the TIGIT/PVR complex and provide structural insights into how the

255 The TIGIT/PVR interface reveals a conserved specific "lock-and-key

256 Notably, two TIGIT/PVR dimers assemble into a heterotetramer with a core TI

257 for primary RRD, recurrent detachment due to PVR occurred in 2 eyes (11.1%).

258 ling procedure (SBP) for recurrent RD due to PVR.

259 outside of the PDGF family)] are relevant to PVR pathogenesis because they act on PDGF receptor alpha

260 Of these patients, 55.7% had none-trace PVR, 32.6% had mild, 8.2% had mild to moderate, and 3.5%

261 Freedom from redo surgical or transcatheter PVR was 98% at 5 years and 96% at 10 years for the whole

262 stdilatation (PD) has been proposed to treat PVR without being formally studied.

263 with repaired tetralogy of Fallot undergoing PVR at our institution between 1988 and 2010.

264 with repaired tetralogy of Fallot undergoing PVR with history of ventricular tachycardia or left vent

265 mean age, 35.8+/-10.1 y; 38 male) undergoing PVR were prospectively recruited for cardiovascular magn

266 reduce ERM formation in patients undergoing PVR-related RD surgery.

267 surgery/radiology, these patients underwent PVR-TIPS to potentiate transplant eligibility.

268 elate with elevated postvoid residual urine (PVR).

269 reoperative proliferative vitreoretinopathy (PVR) and axial length (AL) of the eye upon the anatomica

270 Proliferative vitreoretinopathy (PVR) exemplifies a disease that is difficult to predict,

271 Proliferative vitreoretinopathy (PVR) is a blinding disease associated with rhegmatogenou

272 Proliferative vitreoretinopathy (PVR) is a complication of retinal detachment that can le

273 Proliferative vitreoretinopathy (PVR) is a nonneovascular blinding disease and the leadin

274 Proliferative vitreoretinopathy (PVR) is a serious complication of retinal detachment and

275 Proliferative vitreoretinopathy (PVR) is mediated by proliferation and epithelial mesench

276 pression of proliferative vitreoretinopathy (PVR) patients.

277 ee cases of proliferative vitreoretinopathy (PVR) that developed after successful treatment of retino

278 rade 0 or B proliferative vitreoretinopathy (PVR) was present and higher level 2 failure rates, regar

279 ciated with proliferative vitreoretinopathy (PVR), a sight-threatening complication that develops in

280 out (n = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrhage (n = 10), vitreous opacities (

281 , recurrent proliferative vitreoretinopathy (PVR)-related retinal detachment (n = 18), primary rhegma

282 related to proliferative vitreoretinopathy (PVR).

283 high-grade proliferative vitreoretinopathy (PVR).

284 tion called proliferative vitreoretinopathy (PVR).

285 to prevent proliferative vitreoretinopathy (PVR).

286 established proliferative vitreoretinopathy (PVR).

287 associated proliferative vitreoretinopathy (PVR).

288 (1) grade B proliferative vitreoretinopathy (PVR; n = 917), (2) grade C-1 PVR (n = 637), (3) choroida

289 , 2.6), and proliferative vitreoretinopathy (PVR; OR, 17.6) were statistically significant predictors

290 r example in proliferative vitroretinopathy (PVR) and phthisis bulbi.

291 thing was known about the mechanism by which PVR and DNAM-1 work in TEM.

292 from patients and experimental animals with PVR, and protected rabbits from developing disease.

293 us of patients and experimental animals with PVR, they make only a minor contribution to activating P

294 retinal fibrovascular tissue consistent with PVR, and reactive changes in the retinal pigment epithel

295 In retinal detachments with PVR, tamponade with either gas or silicone oil can be co

296 PAC showed a strong inverse relation with PVR (r=-0.64) and wedge pressure (r=-0.73), and provides

297 min was significantly lower in segments with PVR (74% versus 104%; P<0.001) and was associated with t

298 e cohorts of control patients and those with PVR-A, PVR-B, and PVR-C (n = 10 for each group).

299 atients surviving to 35 years of age without PVR and with a normal exercise capacity may have had a d

300 Compared with segments without PVR (n=758), PVR segments (n=44) were characterized by l